How to Choose the Right CDMO for Your Program

One of the easiest ways to create a messy selection process is to evaluate companies before agreeing on the criteria.

A sponsor may speak with several manufacturers and gradually start favoring whichever one gives the best presentation, responds fastest, or has the strongest brand recognition.

Those factors may matter.

They should not replace the underlying manufacturing requirements.

Before choosing a CDMO, establish what matters most to the program.

Some criteria determine whether a manufacturer is technically viable at all.

Others help the sponsor distinguish between multiple viable options.

The selection process becomes much clearer once those two categories are separated.

A manufacturer should not advance simply because it is well known or has worked on similar programs.

It first needs to appear technically capable of supporting the work.

Technical fit may involve modality, required manufacturing capabilities, production scale, facility characteristics, equipment, regulatory requirements, and other program-specific needs.

For example, a CDMO may offer a broadly relevant service but operate at the wrong scale. Another may support the correct modality but lack a capability required for the sponsor's process.

The purpose of technical screening is to answer:

Can this organization plausibly support the program?

Only then does it make sense to ask whether it is the preferred partner.

CDMO selection should not stop at the parent-company level.

Many contract development and manufacturing organizations operate multiple facilities.

Those sites can differ considerably.

One may specialize in drug substance while another focuses on drug product. One may operate at clinical scale while another supports commercial supply. Equipment, technologies, regulatory history, manufacturing focus, and support services may also vary.

That means the sponsor may not really be selecting:

CDMO A

It may be selecting:

CDMO A, Facility B, for Program C

Where available, facility-level information can make the selection process much more precise.

A large capability list can look impressive.

It does not necessarily mean the CDMO is the right manufacturing partner.

Sponsors should focus on the services and technical capabilities that directly affect the program.

Depending on the product, that may include process development, analytical development, formulation, technology transfer, GMP manufacturing, scale-up, fill finish, testing, drug substance, drug product, or other specialized work.

The question is not:

How much can this CDMO do?

It is:

Can this CDMO do the things this program actually needs?

Scale is easy to overlook during early CDMO selection.

It can become a major issue later.

A manufacturer may support the correct technology but primarily operate at a scale that does not align with the sponsor's current or expected needs.

For an early-stage program, oversized infrastructure may add unnecessary complexity or cost.

For a later-stage program, insufficient scale may create a future bottleneck.

Sponsors should therefore think about current manufacturing requirements and, where appropriate, how those requirements may evolve.

The right partner today should not automatically be assumed to be the right partner for every future stage.

Equipment can be another practical differentiator between otherwise similar CDMOs.

Two facilities may both claim a particular capability but implement it using different manufacturing configurations.

Where structured equipment information is available, it can help sponsors determine which facilities deserve closer technical review.

Equipment information is not a substitute for direct technical discussions with the CDMO.

It can, however, help the sponsor ask better questions and avoid spending time on obviously unsuitable sites.

A preclinical or early clinical biotech company may need something very different from a late-stage pharmaceutical company.

Early programs may benefit from greater flexibility, process-development support, smaller manufacturing scales, and closer collaboration.

Later-stage programs may prioritize robustness, capacity, validation, supply reliability, technology transfer, and commercial readiness.

A strong CDMO selection process asks whether the manufacturer's operating model appears compatible with the current stage of the sponsor's program.

Technical capability and organizational fit are related, but they are not identical.

Some sponsors arrive at a CDMO with a well-defined manufacturing process.

Others need substantial development work.

That difference should influence CDMO selection.

A sponsor that needs formulation support, process development, analytical work, or technology-transfer assistance may prefer a partner with a broader development offering.

A sponsor with a mature process may place greater emphasis on execution, scheduling, manufacturing performance, and commercial terms.

Before selecting a CDMO, define how much help the sponsor actually expects from the manufacturing partner.

That can prevent mismatched expectations later.

Regulatory history can provide useful information during CDMO selection.

PCN gives sponsors access to FDA Form 483 information so facility-level regulatory context can be considered during preliminary diligence.

An FDA Form 483 should not be treated as a simple pass-or-fail indicator.

The observations involved, the facility, subsequent responses, timing, technical relevance, and sponsor-specific quality expectations all matter.

Regulatory information should therefore help generate questions.

It should not replace proper sponsor quality review.

A technically strong CDMO can still be the wrong choice if the project cannot begin when needed.

Sponsors should eventually confirm expected project kickoff, manufacturing timelines, capacity, and scheduling directly with the manufacturer.

During early selection, timing can still help prioritize candidates.

For example, a sponsor with an aggressive clinical timeline may have less flexibility than a team conducting exploratory development work.

The importance of timing should be made explicit before it begins influencing the decision informally.

Some teams strongly prefer a nearby or domestic manufacturing partner.

Others are comfortable working globally.

Neither approach is universally correct.

Geography may affect travel, technology transfer, logistics, regulatory strategy, supply-chain complexity, communication, or internal preferences.

It should be weighted according to the needs of the program.

A geographically convenient CDMO should not automatically outrank a substantially better technical fit unless location is genuinely important to the sponsor.

Budget matters.

But the cheapest quote does not necessarily represent the lowest-risk or best-value manufacturing strategy.

A lower-cost proposal may require compromises in technical support, project management, timing, facility fit, scope, or future scalability.

At the same time, an expensive global CDMO may provide capabilities that an early-stage program does not actually need.

The goal is not to ignore cost.

It is to compare cost in the context of project fit and expected scope.

Selection becomes difficult when every manufacturer is evaluated differently.

One CDMO may be judged primarily on technical expertise, another on cost, another on reputation, and another on how responsive the business-development team was.

That makes comparisons subjective very quickly.

A more disciplined approach is to evaluate potential partners using a consistent set of criteria.

The purpose is not to turn CDMO selection into a spreadsheet exercise.

It is to make the reasoning behind the decision visible.

Reputation matters.

A manufacturer with a strong industry reputation may have significant experience, established systems, and a proven operating history.

But reputation cannot answer every project-specific question.

A well-regarded CDMO may still be the wrong size, wrong facility, wrong scale, wrong timeline, or wrong operating model for a particular sponsor.

Likewise, a less familiar manufacturer may have a specialized facility that aligns very closely with the program.

Brand recognition should therefore be one input, not the selection method.

CDMO selection usually works better when sponsors first narrow the market to a smaller group of credible candidates.

That allows the team to spend more time investigating the manufacturers that have a plausible fit.

The shortlist can then be refined through technical discussions, preliminary diligence, requests for information, proposals, quality review, and other sponsor-specific processes.

For the later stages, the CDMO site visit checklist covers what to review in person, and the CDMO vendor qualification guide explains how a selected manufacturer becomes an approved supplier.

The objective is not to choose a manufacturer from the first search result.

It is to progressively increase confidence.

Once a manufacturer advances to direct conversation, the sponsor should use the meeting to test the assumptions behind the shortlist.

The discussion should go beyond a generic capabilities presentation.

Sponsors should try to understand how the CDMO would support the actual program.

That means asking about the proposed facility, technical approach, scale, timing, support model, project team, regulatory expectations, technology transfer, and any unresolved questions identified during preliminary diligence.

The better defined the program is before the call, the more useful the discussion becomes.

PCN provides a Match % as a project-fit signal.

It can help sponsors understand how closely a manufacturing partner appears to align with the requirements and priorities of a specific program.

A high Match % does not mean that a sponsor can skip diligence, technical evaluation, quality review, commercial discussions, or direct engagement with the manufacturer.

The Match % helps prioritize research and sourcing.

Before committing significant time or confidential information to a potential CDMO, investigate the manufacturer and facility in more detail.

That may include project fit, capabilities, facility information, equipment, scale, and regulatory context.

The purpose is to identify questions that require verification.

A strong preliminary diligence process should make the next stage of CDMO selection more informed.

It should not create false confidence.

Pharma Connect Navigator helps biotech, pharmaceutical, and CMC teams structure the early CDMO selection process.

Sponsors define their manufacturing requirements, identify potential CDMO companies and facilities, compare project fit, investigate available facility-level information, and move toward qualified sponsor-CDMO conversations.

PCN also allows users to adjust the importance of project considerations such as batch size, development stage, project kickoff, budget, geography, and support services.

That makes it possible to refine the search as the sponsor learns more about the program and the manufacturing market.

Once a potential manufacturer appears worth advancing, the sponsor can request a structured introduction.

The CDMO can then review the opportunity and determine whether it may fit.

A useful selection process can be summarized as:

1. Define→
2. Find→
3. Match→
4. Compare→
5. Diligence→
6. Connect→
7. Verify→
8. Select

The early stages narrow the market.

The later stages build confidence.

Skipping directly from discovery to selection can make a manufacturer look more attractive than the available evidence supports.